| Lipids Management |
1 |
1 |
| PCSK9 |
0 |
0.68 |
| Cardiovascular Risk Management |
0 |
0.67 |
| Genomic Medicine |
0 |
0.55 |
| Liver |
0 |
0.5 |
| Aminotransferase |
0 |
0.41 |
| Familial Hypercholesterolemia |
0 |
0.31 |
| Hypercholesterolemia |
0 |
0.25 |
| Gene Editing |
0 |
0.23 |
| LDL Cholesterol |
0 |
0.99 |
| Gene Therapy |
0 |
0.19 |
| Biologic Therapy |
0 |
0.18 |
| Coronary Artery Disease (CAD) |
0 |
0.17 |
| Arrhythmia |
0 |
0.15 |
| Blood |
0 |
0.12 |
| Cardiovascular disease |
0 |
0.12 |
| CRISPR |
0 |
0.12 |
| Infarction |
0 |
0.12 |
| Myocardial Infarction (MI) |
0 |
0.12 |
| Ventricular Tachycardia |
0 |
0.09 |
| Cardiac Arrest |
0 |
0.06 |
| Genetics |
0 |
0.06 |
| Heart |
0 |
0.06 |
| Intravenous |
0 |
0.06 |
| Lipoproteins |
0 |
0.06 |
| Plantar |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Tachycardia |
0 |
0.06 |